Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5301962 | 0.85 | — | — | |
| SCHEMBL13533754 | 0.85 | — | — | |
| SCHEMBL13533879 | 0.85 | — | — | |
| SCHEMBL5074242 | 0.79 | SMN1; SMN2 (0.56) | KDM4EL3MBTL1HSD17B10SMN1; SMN2 | |
| SCHEMBL2647862 | 0.77 | SMN1; SMN2 (0.39) | LMNATSHRHPGDSMN1; SMN2 | |
| SCHEMBL5197245 | 0.76 | TSHR (0.46) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL487980 | 0.75 | LMNA (0.50) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL2239761 | 0.74 | TSHR (0.44) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL21164663 | 0.74 | TSHR (0.44) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL20502579 | 0.74 | TSHR (0.44) | LMNAPLGPLATTSHRGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118772230-A | Long-acting K opioid receptor agonist | 成都奥达生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-116239651-A | Liquid phase synthesis method of diclofenac | 深圳翰宇药业股份有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-101535336-A | Synthetic phthalamides and dimers thereof | SYNTHETIC PEPTIDE AMIDES AND D (US) | 2009-09-16 | — | — | CN | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| CN-118772230-A | Long-acting K opioid receptor agonist | 成都奥达生物科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-3521301-B1 | POLYAMIDE COMPOUND AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20230364096-A1 | USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS | BEONE MEDICINES I GMBH (CH) | 2023-11-16 | — | — | US | disclosed |
| CN-116239651-A | Liquid phase synthesis method of diclofenac | 深圳翰宇药业股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230152316-A1 | SARS-COV2 SPIKE PROTEIN BINDING PEPTIDES | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4146268-A2 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | The Regents of the University of California (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3630771-B1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-0172526-A1 | Benzodiazepines, process for their preparation and their use | Troponwerke GmbH & Co. KG (DE) | 1986-02-26 | — | — | EP | disclosed |
| EP-0042570-B1 | 20-DEOXYROSARAMICIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1983-10-19 | — | — | EP | disclosed |
| EP-0042570-A1 | 20-Deoxyrosaramicin derivatives, process for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4279896-A | Novel 20-imino macrolide antibacterial agents | SCHERING CORPORATION (US) | 1981-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | LMNA 2123/4885PLG 1951/4885PLAT 2284/4885 |
| US-20230364096-A1 | USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS | BTK, LCK, LYN | LMNA 4464/4885PLG 4628/4885PLAT 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.